Contact

3023882345 (Home)
ranjanmuk@comcast.net

www.linkedin.com/in/ranjanmukherjee1 (LinkedIn)

Top Skills

Drug Discovery

Discovery Biology

Cross-functional Team Leadership

Languages

Hindi (Professional Working)

Bengali (Native or Bilingual)

Honors-Awards

National Science Talent Scholar

Publications

The winding road

A Selective PPARgamma Modulator Blocks Adipocyte Differentiation but Stimulates Glucose uptake in 3T3-L1 Adipocytes

World must stop ignoring the plight of Myanmar's Rohingyas

Living Free, Living Well: My Life as a Zen Bon Vivant. How I Retired at 58: A Guide & Memoir

Sensitization of diabetic and obese Mice to Insulin by Retinoid X Receptor Agonists

Ranjan Mukherjee, Ph.D.

Author, Speaker, Traveler, and Retired Scientist
Greater Philadelphia

Summary

SUMMARY:

Author of "LIVING FREE, LIVING WELL: MY LIFE AS A ZEN BON VIVANT. HOW I RETIRED AT 58: A GUIDE AND MEMOIR" available on Amazon.

Writer, editor and speaker specializing in travel, current events, and happy, healthy living. Published in Science, Philadelphia Inquirer, AAA-WORLD, Courier Times, The Intelligencer and blogs.
For selected samples of my work, please see my website www.ranjanmukherjee.com/

Twenty-two years of experience in Pharmaceutical Drug Discovery and Early Development. Exceptional aptitude for oral and written presentations. Proven track record in initiating and leading multi-disciplinary programs (small molecules and biologics) and delivering results.

Experience

Greater Philadelphia area

Writer, Speaker, Editor and Independent Consultant
January 2014 - Present (11 years 9 months)

Author of "LIVING FREE, LIVING WELL: MY LIFE AS A ZEN BON VIVANT. HOW I RETIRED AT 58: A GUIDE & MEMOIR" available on Amazon and IngramSpark.

Writer, traveler and speaker specializing in travel, science and career transitions. Published in AAA-WORLD, Science, Philadelphia Inquirer, Courier Times, The Intelligencer and blogs. For samples of these writings please see my website and blog www.ranjanmukherjee.com/

Independent Consultant for Medical Writing, Scientific Presentations, Drug Discovery and Due Diligence.

Expertise in:
• Diabetes, obesity, insulin sensitization, cardiovascular diseases, inflammation, kidney disease, fibrosis, NASH, specialist in nuclear receptors
• Writing manuscripts and publishing in top tier scientific journals
• Writing reports for IND submission, IBs, book chapters and patents
• Oral and poster presentations at national and international conferences
• Evaluating drug candidates and technologies for licensing, due diligence
Selected scientific publications are shown below.

Bristol-Myers Squibb

10 years

Senior Principal Scientist

2007 - December 2013 (6 years)

Hopewell, NJ

Proposed and evaluated new targets and initiated early drug discovery efforts for diabetes. Co-chair of multi-disciplinary drug discovery teams including in vitro and in vivo biology, chemistry, protein design and production, toxicology, regulatory, marketing and clinical development.

• Proposed and initiated the first protein therapeutic program for the diabetes portfolio at BMS. This was a novel approach and involved use of an adnectin as a pharmacokinetic enhancer linked to a heterologous protein (FGF21). Co-chair of the team that delivered an Early Clinical Nominee (FGF21-Adnectin-PKE) within 2 years from initiation of the program. Oral presentation in the session on Novel Agents for Diabetes Management at the American Diabetes Association 72nd Scientific Sessions, Philadelphia, 2012.
• Pharmacology lead for BMS-986036 (pegylated-FGF21), now in Phase II clinical trials for NASH. Responsible for pharmacology reports for IND filing and Investigator Brochure. Subject matter expert for FGF21 on the Clinical Development Team in the BMS-Ambrx partnership. Co-chaired the back-up program.
• Led a strategy team to evaluate novel insulins/mimetics for treating diabetes. Proposed a unique antibody approach and co-chaired the discovery team.
• Proposed and led 4 exploratory programs for diabetes and quickly brought them to data driven no-go decision.

Principal Scientist

2003 - 2007 (4 years)
Hopewell, NJ

• Initiated and co-chaired the PPARalpha selective agonist program for atherosclerosis. Delivered an Early Candidate Nominee (ECN) for clinical development. Results published and highlighted in the Journal of Pharmacology and Experimental Therapeutics (2008) and in Journal of Medicinal Chemistry (2010).
• Conceptualized and developed a liver gene induction assay after a single oral dose in animals that enabled analysis of in vivo activity for PPARalpha agonists within hours of treatment. This led to significant lowering of compound requirements and experimental time. The team received a Triumph Award for developing this assay which served as a prototype for other programs.

DuPont Pharmaceuticals

Senior Research Investigator II

1999 - 2002 (3 years)
Wilmington, DE

Initiated and concurrently led three new exploratory programs in cardiovascular diseases. Two programs (LXR and PPARalpha agonist programs) were evaluated and continued after BMS acquisition. Three manuscripts published describing the concepts and assays established.

Ligand Pharmaceuticals

7 years

Research Investigator

1997 - 1999 (2 years)
San Diego, CA

• Led a team to identify gene signatures of PPAR and RXR ligands in cell lines and animal models for use as translational biomarkers.

• Identified one of the first selective PPARgamma modulators, published and highlighted on the cover of Molecular Endocrinology (2000).

Senior Research Scientist

1995 - 1997 (2 years)
San Diego, CA

• Demonstrated the potential for RXR agonists in the treatment of diabetes and cardiovascular diseases and synergistic effects with PPAR agonists. Results were published in Nature (1997) and Atherosclerosis, Thrombosis and Vascular Biology (1998). These results led to the initiation of the Ligand/Eli-Lilly collaboration, one of the largest alliances for biotech.

Research Scientist
1992 - 1995 (3 years)
San Diego, CA

• Initiated the PPAR program as part of the cardiovascular collaboration with Glaxo Pharmaceuticals, UK (now GlaxoSmithKline) that led to a clinical candidate.

DuPont-Merck Pharmaceuticals Company
Visiting Scientist
1991 - 1992 (1 year)
Wilmington, DE

INSERM
Post-Doctoral Fellow. Advisor, Prof. Pierre Chambon
1988 - 1991 (3 years)
Strasbourg, France

Education

University of Delaware
Ph.D., Biology

University of Calcutta
M.Sc., Physics

University of Calcutta
B.Sc., Physics (Honors)